Tech mogul donates $250 million for collaborative cancer immunotherapy research

One of Silicon Valley’s highest profile stars is turning his attention to the fight against cancer with a $250 million donation to support immunotherapy research. Sean Parker, co-founder of Napster and the first president of Facebook, announced the grant Wednesday, April 13.

The establishment of the Parker Institute for Cancer Immunotherapy will include more than 40 laboratories and 300 researchers from six cancer centers, including New York’s Memorial Sloan Kettering and Stanford Medicine in California. The goal is to encourage collaboration with researchers sharing discoveries, exchanging data and conducting joint clinical trials.

"Any breakthrough made at one center is immediately available to another center without any kind of [intellectual property] entanglements or bureaucracy," Parker told Reuters in an interview.

The institute, which will be based in San Francisco, will emphasize research in three main areas: modifying a patient's own immune system to target a tumor, studying ways to boost patient response to current immunotherapy drugs, and research to identify other novel methods of attacking tumors.

"There have been other cancer therapies that attracted significant funding, particularly from pharmaceutical companies, but I've never seen anything this big," said Otis Brawley, MD, chief medical officer for the American Cancer Society, which is not associated with the new endeavor. "Given the number of good ideas that don't get funded, $250 million is huge."

""
Nicholas Leider, Managing Editor

Nicholas joined TriMed in 2016 as the managing editor of the Chicago office. After receiving his master’s from Roosevelt University, he worked in various writing/editing roles for magazines ranging in topic from billiards to metallurgy. Currently on Chicago’s north side, Nicholas keeps busy by running, reading and talking to his two cats.

Around the web

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”